Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”

(2021) Rossella Talotta   CLINICAL IMMUNOLOGY

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

(2021) Isaac See et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?

(2021) Søren Dinesen Østergaard et al.   LANCET

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

(2021) Marie Scully et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

(2021) Kate-Lynn Muir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE